Oncolytics Biotech Inc.
) shares gained 2.7% following the company's announcement that it
has finished enrolling patients in an open-label,
multi-institution, two-arm randomized phase II study (OSU-10045) on
its oncology candidate, Reolysin. Shares jumped a further 7.8% in
the subsequent trading session. Shares are up 8% since the
The study (n=70) will evaluate Reolysin plus carboplatin and Taxol
(Arm A) in comparison with carboplatin and Taxol alone (Arm B) as a
first-line treatment of patients with recurrent or metastatic
pancreatic cancer. The primary endpoint of this study is
This study is sponsored by the U.S. National Cancer Institute.
We note that Reolysin is the main candidate in Oncolytics' pipeline
and is being studied for different indications. Later this year,
data from a randomized phase II study for ovarian cancer should be
According to the American Cancer Society, 46,420 people in the U.S.
are expected to be diagnosed with pancreatic cancer in 2014, with
approximately 39,590 deaths expected due to the disease. The
prognosis for pancreatic cancer patients, according to Oncolytics,
is poor, irrespective of the stage of illness.
Given the five-year survival rate of about 6%, we believe there is
need for new treatments in the pancreatic cancer market.
Some drugs approved for the treatment of pancreatic cancer are
) Abraxane and
Oncolytics carries a Zacks Rank #2 (Buy). A better-ranked stock in
the biotech sector is
Biogen Idec Inc.
), carrying a Zacks Rank #1 (Strong Buy). Celgene holds a Zacks
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
LILLY ELI & CO (LLY): Free Stock Analysis
CELGENE CORP (CELG): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
ONCOLYTICS BIO (ONCY): Free Stock Analysis
To read this article on Zacks.com click here.